Advanced gastric and gastroesophageal junction cancers are receiving renewed attention after researchers reported a clinical study testing a three-part first-line treatment strategy that combines immunotherapy, targeted anti-angiogenic therapy and chemotherapy. The study, led by Cheng, Zhang, Hu and colleagues, investigates sintilimab together with IBI305, a biosimilar version of bevacizumab, and conventional chemotherapy in patients with […]